Comparison of Intranasal Oxytocin Effects Using Co-administration With a Vasoconstrictor
NCT ID: NCT04134663
Last Updated: 2022-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
96 participants
INTERVENTIONAL
2019-03-02
2021-07-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Intranasal application of the neuropeptide oxytocin has been reported to produce a number of neural, physiological and behavior effects which may be of potential therapeutic relevance, but it is unclear the extent to which they are mediated directly via the peptide entering the brain or indirectly as a result of increased peripheral concentrations. In the current placebo-controlled, double blind experiment on healthy adult male subjects the investigators will measure the effects of a single dose of intranasal oxytocin (24IU) on brain activity (using electroencephaolography - EEG) as well as on cardiac (heart-rate and heart-rate variablility) and gastric (electrogastrogram - EGG) activity and physiological arousal (skin conductance response - SCR). The pattern of functional effects observed will be compared with subjects receiving intranasal pretreatment with a vasoconstrictor prior to oxytocin in order to reduce the amount of oxytocin entering the peripheral circulation. The investigators hypothesize that prior administration of the vasoconstrictor will greatly reduce blood oxytocin concentrations following intranasal oxytocin treatment. Where neural/physiological effects are also affected, this will indicate an indirectly mediated action of intranasally administered oxytocin whereas if they are not this will indicate a directly mediated action.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epinephrine Nasal Drops for Epistaxis During Nasal Intubation
NCT06789549
Effect of Dexmedetomidine on Hemodynamic Response to Endotracheal Intubation in Hypertensive Patients
NCT06712186
Nasal Dexmedetomidine Versus Systemic Infusion Dexmedetomidine in Reducing Intraoperative Opioid Consumption in Nasal Endoscopic Surgeries
NCT07012213
Adrenaline Nasal Pack vs Xylometazoline Nasal Drops During Nasotracheal Intubation
NCT06801522
Dexmedetomidine Infusion Dose Versus Rapid Bolus Dose Before Tracheal Intubation.
NCT06327399
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vasoconstrictor + intranasal oxytocin group
subjects receive the vasoconstrictor followed by oxytocin
vasoconstrictor and oxytocin treatment
intransal administration of vasoconstrictor and oxytocin
vasoconstrictor's placebo + intranasal oxytocin group
subjects receive the vasoconstrictor's placebo followed by oxytocin
vasoconstrictor's placebo and oxytocin treatment
intransal administration of vasoconstrictor's placebo and oxytocin
vasoconstrictor + intranasal oxytocin placebo group
subjects receive the vasoconstrictor followed by intranasal oxytocin's placebo
vasoconstrictor and oxytocin's placebo treatment
intransal administration of vasoconstrictor and oxytocin's placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vasoconstrictor and oxytocin treatment
intransal administration of vasoconstrictor and oxytocin
vasoconstrictor's placebo and oxytocin treatment
intransal administration of vasoconstrictor's placebo and oxytocin
vasoconstrictor and oxytocin's placebo treatment
intransal administration of vasoconstrictor and oxytocin's placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* medical or psychiatric illness.
18 Years
30 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Electronic Science and Technology of China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Keith Kendrick
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
school of life science and technology, University of Electronic Science and Technology of China
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UESTC-neuSCAN-43
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.